We are live on ! Find out more
EDIT icon

Editas Medicine

99 hedge funds and large institutions have $614M invested in Editas Medicine in 2017 Q1 according to their latest regulatory filings, with 35 funds opening new positions, 32 increasing their positions, 17 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 15

88% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 17

61% more capital invested

Capital invested by funds: $381M → $614M (+$233M)

18% more funds holding

Funds holding: 8499 (+15)

3.54% more ownership

Funds ownership: 64.09%67.63% (+3.5%)

31% less call options, than puts

Call options by funds: $5.38M | Put options by funds: $7.75M

50% less funds holding in top 10

Funds holding in top 10: 42 (-2)

Holders
99
Holders Change
+15
Holders Change %
+17.86%
% of All Funds
2.46%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.05%
New
35
Increased
32
Reduced
17
Closed
15
Calls
$5.38M
Puts
$7.75M
Net Calls
-$2.37M
Net Calls Change
-$2.61M
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$132M +$8.35M +403,099 +7%
PVMCV
2
Polaris Venture Management Co VI
Massachusetts
$84.8M
FP
3
Flagship Pioneering
Massachusetts
$75.4M -$1.64M -79,132 -2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$43.2M +$12.8M +618,789 +47%
Capital World Investors
5
Capital World Investors
California
$39.5M +$30.6M +1,475,000 +500%
DM
6
Deerfield Management
New York
$38.2M
Viking Global Investors
7
Viking Global Investors
Connecticut
$38.2M
T. Rowe Price Associates
8
T. Rowe Price Associates
Maryland
$31.3M -$4.76M -229,838 -14%
BlackRock
9
BlackRock
New York
$25M +$23.2M +1,118,228 +430,088%
Millennium Management
10
Millennium Management
New York
$12.6M +$11.5M +554,200 +5,279%
CCP
11
Clough Capital Partners
Massachusetts
$8.75M +$7.08M +341,687 +678%
Morgan Stanley
12
Morgan Stanley
New York
$6.89M +$2.08M +100,585 +48%
D.E. Shaw & Co
13
D.E. Shaw & Co
New York
$5.47M +$4.7M +226,652 +1,240%
AIM
14
ARK Investment Management
Florida
$5.13M +$4.76M +229,922 New
HCMT
15
Highland Capital Management (Texas)
Texas
$4.22M +$2.05M +99,000 +110%
Susquehanna International Group
16
Susquehanna International Group
Pennsylvania
$3.66M +$2.68M +129,435 +373%
CS
17
Credit Suisse
Switzerland
$3.44M -$1.5M -72,168 -32%
LP
18
LMR Partners
United Kingdom
$3.42M +$3.17M +153,190 New
YCMGA
19
York Capital Management Global Advisors
New York
$3.35M +$3.11M +150,000 New
CC
20
Casdin Capital
New York
$2.98M +$1.42M +68,333 +105%
State Street
21
State Street
Massachusetts
$2.96M +$569K +27,451 +26%
DCM
22
Driehaus Capital Management
Illinois
$2.81M +$1.64M +79,104 +170%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$2.66M +$112K +5,397 +5%
SC
24
Shellback Capital
Massachusetts
$2.56M +$2.37M +114,461 New
Northern Trust
25
Northern Trust
Illinois
$2.41M +$380K +18,338 +20%

EDIT Hedge Fund Activity: Q1 2017 in Review

99 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q1 2017, worth a combined $614M — up 61% from $381M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new EDIT positions and 15 closed out — a net gain of 20 holders — while 32 added to existing stakes and 17 trimmed.

The largest buyer was Capital World Investors, adding an estimated $30.6M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $10.2M sold.

  • 99 institutional investors held Editas Medicine (EDIT) as of Q1 2017, up from 84 in Q4 2016.
  • Funds reported $614M of Editas Medicine stock for Q1 2017, up 61% quarter-over-quarter.
  • 35 funds opened new Editas Medicine positions in Q1 2017 and 15 closed out, a net change of +20 holders.
  • The largest Editas Medicine buyer in Q1 2017 was Capital World Investors, an estimated $30.6M added.
  • The largest Editas Medicine seller in Q1 2017 was EcoR1 Capital, an estimated $10.2M sold.

Based on aggregated 13F filings for Q1 2017.